^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) + lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) + Calquence (acalabrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
73 Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma
Published date:
11/03/2022
Excerpt:
This study demonstrates that triple chemo-free combination of acalabrutinib-lenalidomide-rituximab (ALR) is well tolerated, highly effective, and produces high rates of MRD-negative CR as initial treatment for MCL, including high risk patients with TP53 mutations.
DOI:
https://doi.org/10.1182/blood-2022-158656
Trial ID:
